Pharmacologic Agents for Tobacco Dependence Treatment: 2011 Update
- 249 Downloads
Tobacco use remains the most important worldwide cause of preventable death due mainly to cancer, cardiovascular disease, and chronic lung disease. If the current tobacco pandemic continues for another 20 years, the annual global tobacco-attributable mortality will exceed 8 million. In the US and many European countries, public health and tobacco control efforts combined with effective tobacco dependence treatment using combined behavioral treatment and pharmacotherapy have contributed significantly to steadily declining rates of tobacco use. Subsequent declines in cardiovascular disease and lung cancer death rates are directly attributable to these lower rates of tobacco use. Despite smoking bans, health warnings and effective pharmacotherapy, one in five Americans continue to smoke. Continued research in tobacco dependence treatment has resulted in newer and more effective pharmacotherapy. In this review, we provide a current update of pharmacologic agents for tobacco dependence treatment and a discussion of recent controversy regarding adverse effects of some these medications.
KeywordsTobacco dependence Pharmacotherapy Cardiovascular disease
J.T. Hays has received grants (paid to his institution) from Pfizer and Nabi Biopharmaceuticals. D.D. McFadden had Pfizer reimburse his institution (Mayo Clinic) for Pfizer-sponsored tobacco treatment seminars he conducted in Mexico and South America; Pfizer also covered his travel expenses for those seminars. J.O. Ebbert has been a consultant for and had travel expenses reimbursed by GlaxoSmithKline, and has also received a grant (paid to his institution) from Pfizer.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 1.Shafey O, Eriksen M, Ross H, Mackay J. The Tobacco Atlas. 3rd ed. Atlanta: American Cancer Society; 2009.Google Scholar
- 5.Fiore MC, Jaen CR, Baker TB et al. Treating tobacco use and dependence: 2008 update. Clinical Practice Guidelines. In: Rockville, MD: U.S. Department of Health and Human Services. Public Health Service; May 2008.Google Scholar
- 6.Stead LF, Perera R, Bullen C et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2008:CD000146.Google Scholar
- 7.• Piper ME, Smith SS, Schlam TR et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry. 2009, 66:1253–62. This clinical trial demonstrated the efficacy of combination pharmacotherapy by randomizing 1504 patients to 1 of 6 treatment conditions: nicotine lozenge, nicotine patch, sustained-release bupropion, nicotine patch plus nicotine lozenge, bupropion plus nicotine lozenge, or placebo. The nicotine patch plus lozenge produced the greatest benefit relative to placebo for smoking cessation. PubMedCrossRefGoogle Scholar
- 8.• Smith SS, McCarthy DE, Japuntich SJ et al.: Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. Arch Intern Med. 2009;169:2148–55. This study demonstrates the effectiveness of combination pharmacotherapy in a primary care clinic setting. A total of 1346 primary care patients were randomly assigned to 1 of 5 treatments: 3 monotherapies (nicotine patch, nicotine lozenge, and bupropion hydrochloride sustained release [SR]) and 2 combination therapies (patch + lozenge and bupropion SR + lozenge). Combination pharmacotherapy significantly increased abstinence compared with monotherapies. PubMedCrossRefGoogle Scholar
- 10.• Schnoll RA, Patterson F, Wileyto EP et al.: Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial. Ann Intern Med. 2010;152:144–51. In a clinical trial randomizing 568 smokers to extended use nicotine patch (24 weeks) compared with standard 8-week therapy, extended-duration therapy was superior to standard therapy at both 24 weeks and 52 weeks. PubMedGoogle Scholar
- 19.Lindson N, Aveyard P, Hughes JR. Reduction versus abrupt cessation in smokers who want to quit. Cochrane Database Syst Rev. 2010:CD008033.Google Scholar
- 20.• Mills EJ, Wu P, Lockhart I, et al. Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals. Tob Induc Dis 2010, 8:8. In one of the largest meta-analyses of NRT adverse effects published to date, NRT adverse effects were found to be mild overall, and there was no increase in serious adverse events such as depression or anxiety. PubMedCrossRefGoogle Scholar
- 22.Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2007:CD000031.Google Scholar
- 36.Alwan S, Reefhuis J, Botto LD, et al. Maternal use of bupropion and risk for congenital heart defects. Am J Obstet Gynecol. 2010;203(52):e51–6.Google Scholar
- 39.• Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2011:CD006103. This large systematic review observed that varenicline increased the chances of successful long-term smoking cessation between two- and threefold compared with pharmacologically unassisted quit attempts. Varenicline was also observed to be superior to bupropion. The main adverse effect of varenicline is nausea but mostly at mild to moderate levels and tending to subside over time. Google Scholar
- 42.U.S. Food and Drug Administration. FDA Drug Safety Communication: Chantix (varenicline) may increase the risk of certain cardiovascular adverse events in patients with cardiovascular disease. Available at http://www.fda.gov/Drugs/DrugSafety/ucm259161.htm. Accessed June 2011.
- 43.• Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ. 2011, July 5 [Epub ahead of print]. This meta-analysis of serious cardiovascular events associated with varenicline shows a small but statistically significant increase in cardiovascular events with varenicline compared with placebo. Google Scholar
- 44.Hays JT. Varenicline for smoking cessation: is it a heartbreaker? CMAJ. 2011, July 5 [Epub ahead of print].Google Scholar
- 45.U.S. Food and Drug Administration. The smoking cessation aids varenicline (marketed as chantix) and bupropion (marketed as zyban and generics): suicidal ideation and behavior. FDA Safety Newsletter. 2009;2:1–4.Google Scholar
- 46.• Gunnell D, Irvine D, Wise L et al. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ. 2009, 339:b3805. In a retrospective analysis of 10,973 tobacco-dependent patients who used varenicline in a general practice setting, varenicline treatment was associated with similar rates of depression, self-harm, and suicidal thoughts as NRT. This further supports the growing body of medical literature questioning the causal relationship of varenicline to worsening depression and suicidal ideation. PubMedCrossRefGoogle Scholar